Tokai Pharmaceuticals, a developer of new treatments for prostate cancer, has raised $35.5 million in a Series E round of financing from Apple Tree Partners, Novartis Venture Funds and individual investors. The Cambridge, MA-based company’s lead drug candidate, galeterone, is an oral drug that “disrupts androgen receptor signaling.” The proceeds will be used to expand the ongoing Phase 2 clinical trial of galeterone in patients with castrations-resistant prostate cancer.
